PubRank

Reply to: 'NAFLD or comorbidities, that is the question'.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 32407814)

Published in J Hepatol on May 12, 2020

Authors

Dong Ji1, Dawei Zhang1, George Lau2

Author Affiliations

1: The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
2: The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China; Humanity and Health Clinical Trial Center, Humanity & Health Medical Group, Hong Kong SAR, China. Electronic address: gkklau@hnhmgl.com.

Articles by these authors ⇆

Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol (2020) 4.99

Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'. J Hepatol (2020) 0.75

Reply to: 'Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis'. J Hepatol (2020) 0.75